cells rs1  (ATCC)

Journal: Cell Reports

Article Title: The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

doi: 10.1016/j.celrep.2021.109679

Figure Lengend Snippet:

Article Snippet: B.1.1.7 rS1-SARS-CoV-2 spike S1 [Δ 69-70; Δ 144; N501Y; A570D ; D614G; P681H] , Sino Biologicals , Cat#40591-V08H12.

Techniques: Virus, Variant Assay, Recombinant, Software

Journal: Cell Reports

Article Title: The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

doi: 10.1016/j.celrep.2021.109679

Figure Lengend Snippet: mAb binding of singly mutated rRBDs Binding of the WT and the six indicated singly mutated rRBDs by MD65 (A), MD62 (B), MD29 (C), BL6 (D), and LY-CoV555 (E) mAbs was evaluated by biolayer interferometry (BLI). Each mAb was immobilized on a protein A sensor and incubated with each of the rRBD mutants (N501Y, S477N, E484K, N439K, K417N, and Y453F; depicted in Figure S3 A) or WT rRBD as a control for 180 s. The figure includes representative graphs of at least two independent repeats of each experiment, yielding similar results.

Article Snippet: B.1.351 rS1-SARS-CoV-2 spike S1 [K417N; E484K; N501Y; D614G] , Sino Biologicals , Cat#40591-V08H10.

Techniques: Binding Assay, Incubation

Journal: Cell Reports

Article Title: The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

doi: 10.1016/j.celrep.2021.109679

Figure Lengend Snippet: Structural basis of MD65 binding to COVID-19 spike variants determined by comparative modeling to the CovA2-04 mAb (A) Alignment of the primary amino acid sequences of the heavy (two upper sequences) and light (two lower sequences) chain variable domains of the two antibodies compared (CovA2-04 in pink and MD65 in cyan). Diverged residues are indicated by bold and underlined letters. (B–D) MD65 model structure (cyan) aligned with CovA2-04 crystal structure (pink; WT [PDB: 7jmo ] and B.1.351 spike [PDB: 7nxa ], violet and green, respectively). (B) A view of the superimposed variable domain models of the two mAbs, indicating the close correspondence of the MD65 model structure and the experimentally determined structure of CovA2-04. (C) The Lys residue at position 417 of the WT spike protein forms a stabilizing hydrogen bond (dashed line) with the Glu residue at position 100 of CovA2-04. The K417N present in B.1.351 abrogates this stabilizing interaction leading to potential strain in binding to the negative surface on the complementarity-determining region (CDR) H3 loop of CovA2-04. The Ala at the analogous position in MD65 may relieve this strain. (D) The small-to-large N501Y substitution on the B.1.351 spike may physically overlap with the CDR L1 of CovA2-04. The V29I difference in MD65 (compared with CovA2-04) modifies the CDR L1 backbone conformation, expanding the space in this region for the bulkier Tyr residue of the spike.

Article Snippet: B.1.351 rS1-SARS-CoV-2 spike S1 [K417N; E484K; N501Y; D614G] , Sino Biologicals , Cat#40591-V08H10.

Techniques: Binding Assay

Journal: Cell Reports

Article Title: The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

doi: 10.1016/j.celrep.2021.109679

Figure Lengend Snippet: Binding of rS1 variants by RBD-specific mAbs (A–E) BLI was applied to evaluate the ability of each tested mAb to bind the indicated recombinant multiply mutated spike S1 subunit proteins: B.1.1.7 rS1 (Δ 69–70; Δ 144; N501Y; A570D; D614G; P681H; Figure S3 B) and B.1.351 rS1 (K417N; E484K; N501Y; D614G; Figure S3 C). Each of the indicated mAbs (A–E) was immobilized on protein A sensor and incubated for 180 s with B.1.1.7 (blue) or B.1.351 (red) rS1 variants or with the WT rS1 (black). (F) Non-specific control antibody (anti-ricin MH75) was included. The figure includes representative graphs of at least two independent repeats of each experiment, yielding similar results.

Article Snippet: B.1.351 rS1-SARS-CoV-2 spike S1 [K417N; E484K; N501Y; D614G] , Sino Biologicals , Cat#40591-V08H10.

Techniques: Binding Assay, Recombinant, Incubation

Journal: Cell Reports

Article Title: The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

doi: 10.1016/j.celrep.2021.109679

Figure Lengend Snippet: Neutralization of SARS-CoV-2 B.1.1.7 and B.1.351 by RBD and NTD-specific mAbs (A–G) Neutralization capacity of the RBD-specific mAbs, MD65 (A), MD62 (B), MD29 (C), BL6 (D), and LY-CoV555 (E) and of the NTD-specific BLN14 (F) and BLN12 (G) was evaluated by plaque reduction neutralization test (PRNT). The in vitro neutralization of each of the listed mAbs was assessed against both SARS-CoV-2 B.1.1.7 (blue) and B.1.351 (red) variant, compared with WT SARS-CoV-2 strain (black). Neutralization potency was determined by the ability of each antibody (at indicated concentrations) to reduce plaque formation. Results are expressed as percent inhibition of control without Ab. Values along the curve depict averages of triplicates ± SEM. The figure includes a representative graph of at least two independent repeats of each experiment, yielding similar results. (H) Summary of the calculated IC 50 values (μg/ml). IC 50 > 10,000 indicates complete loss of neutralization capacity, emphasized by gray shading. The neutralization results, together with previously published biochemical data of the six inspected mAbs, are summarized in .

Article Snippet: B.1.351 rS1-SARS-CoV-2 spike S1 [K417N; E484K; N501Y; D614G] , Sino Biologicals , Cat#40591-V08H10.

Techniques: Neutralization, Plaque Reduction Neutralization Test, In Vitro, Variant Assay, Inhibition

Journal: Cell Reports

Article Title: The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

doi: 10.1016/j.celrep.2021.109679

Figure Lengend Snippet: Post-exposure therapeutic potency of MD65, BL6, and BLN14 in K18-hACE2 mice infected with various SARS-CoV-2 strains The SARS-CoV-2 strains are indicated in the left vertical lane and the administered antibodies in the legends within each individual panel (colored differently). A single dose of 1 mg Ab/animal of each indicated mAb (n = 6 per experimental group) or PBS for the control groups (n ≥ 7) was administered at day 2 after viral infection. Left panels: body weight profiles. Body weight is displayed as percentage change of initial weight (average ± SEM). Only data of the first 6 days are presented in the control groups exhibiting significant mortality. Right panels: Kaplan-Meier survival curves.

Article Snippet: B.1.351 rS1-SARS-CoV-2 spike S1 [K417N; E484K; N501Y; D614G] , Sino Biologicals , Cat#40591-V08H10.

Techniques: Infection

Journal: Cell Reports

Article Title: The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

doi: 10.1016/j.celrep.2021.109679

Figure Lengend Snippet:

Article Snippet: B.1.351 rS1-SARS-CoV-2 spike S1 [K417N; E484K; N501Y; D614G] , Sino Biologicals , Cat#40591-V08H10.

Techniques: Variant Assay, Recombinant, Software